What is EBCC?
The most exciting breast cancer conference in Europe, it is the only one that involves all the major players in breast cancer. The conference encourages interaction and collaboration between clinicians, scientists and patients in a partnership of equals to talk not just about scientific advances, but also the ethical, social, political, and practical issues associated with caring for patients with breast cancer. EBCC-6 is expected to attract over 5000 delegates from around 90 countries worldwide.
Here is a sample of the new results to be announced at the conference (embargoed to time of presentation at EBCC-6):
Hereditary breast cancer a high cost to patient and healthcare provider alike; why women may choose prophylactic mastectomy rather than go through years of stressful screening programmes
How obese women are doubly disadvantaged; they do worse in both breast cancer treatment and diagnosis
MRI before surgery can lead to better adapted treatment for breast cancer; should this become a standard procedure"
Pregnant patients lose out in breast cancer treatment; a new approach is needed
New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
Are aromatase inhibitors associated with increased heart problems" Important new evidence
New type of drug shrinks primary breast cancer tumours significantly in just six weeks; research provides leads to a new target in breast cancer treatment the stem cell
Chemotherapy for metastatic breast cancer: does it work best against sporadic tumours, or those associated with a BRCA1/2 genetic mutation"
Breast cancer screening: is an annual mammogram better than a three-yearly one, and should women continue to be screened up to the age of 75" New evidence
Can acupuncture provide effective relief from hot flushes in women who are suffering menopause-like symptoms as a result of taking tamoxifen"
Results from the largest multi-centre trial to investigate the combination of trastuzumab and neoadjuvant chemotherapy for women with HER2 positive tumours provides surprising new data on safety and efficacy
New study reveals that countries could save millions of Euros on follow-up care for breast cancer patients
Breast tumours behave differently depending on whether women are older or younger than 70. Is the immune system involved"
There will be news briefings in English on Wednesday (10am), Thursday (10am) and Friday (9am) and in German on Wednesday (11am).
|Contact: Mary Rice|
ECCO-the European CanCer Organisation